US Patent

US10105323 — Pharmaceutical dosage form for immediate release of an indolinone derivative

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-06-04 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical dosage form that delivers an immediate release profile of the active substance nintedanib esylate.

USPTO Abstract

The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Drugs covered by this patent

Patent Metadata

Patent number
US10105323
Jurisdiction
US
Classification
Formulation
Expires
2029-06-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.